Terumo : Formulates 5-Year Mid- to Long-term Growth Strategy -Aim to Expand in a Ten-Year Perspective as a Global Corporation with Japanese Origins
December 11, 2016 at 10:50 pm EST
Share
December 12, 2016
TOKYO, JAPAN - Dec. 12, 2016 - Terumo Corporation (TSE: 4543) announced today that it has formulated its 5-year Mid- to Long-term Growth Strategy starting from April, 2017. As a global corporation with Japanese origins, we will achieve profitable and sustainable growth by executing the following strategies in a ten-year perspective.
Mid- to Long-term Growth Strategy
1. Win in selected strategic markets
Select growing segments and segments where Terumo owns a competitive advantage
oncentrate on intervention, neurovascular, D&D, and therapeutic apheresis
2. Offer comprehensive value in Japan
Leverage leading position and pursue growth opportunities
3. Accelerate innovation
Contribute to future of healthcare with significant social impact
Advance core technologies and gain new technologies
Management Indicators for the Next Five Years
(Plan FX rate: USD=105 JPY, EUR=115 JPY)
Growth:
Faster revenue growth than market growth
High single-digit growth in revenue
Profitability:
Faster profit growth than revenue growth
Double-digit growth in profit*
Adjusted EPS** 270 - 300 yen by 2021
Efficiency:
Maintain ROE 10%+***
* Adjusted operating income (IFRS)
** Adjusted items: Intangible asset derived from acquisition, one time acquisition expense, impairment, gain/loss from sales of stocks and others
***Excluding foreign currency translation adjustment balance related to the assets from acquisition included in net assets
For more information, visit http://www.terumo.com/investor/library/material.html
(Notice) Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. The market share information in this press release is partly derived from our own independent research.
Terumo Corporation published this content on 12 December 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 12 December 2016 03:50:02 UTC.
Original documenthttp://www.terumo.com/about/pressrelease/2016/20161212.html
Public permalinkhttp://www.publicnow.com/view/07ABD7FABD98CB13986F020632FF067FF6F2AFDF
Terumo Corporation specializes in the design, manufacturing and marketing of medical products and equipments. Net sales break down by family of products as follows:
- cardiac surgery devices (53.5%);
- medical products for hospitals (28.6%): medical devices, nutritional additives, oxygen, medical measuring devices (thermometers, tensiometers, glucometers, etc.), etc.;
- sanguine transfusion equipments (17.9%).
Net sales break down geographically as follows: Japan (32.9%), America (29.5%), Europe (19.6%), China (7.4%) and other (10.6%).